Asma BOURAFAI AZIEZ

Dr. Asma BOURAFAI AZIEZ

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
FWFabien Wauquier
Fabien Wauquier
LBLine BOUTIN-WITTRANT
Line BOUTIN-WITTRANT
AVAurélien Viret
Aurélien Viret
LGLaure Guilhaudis
Laure Guilhaudis
HOHassan Oulyadi
Hassan Oulyadi
yohann wittrantyohann wittrant
yohann wittrant
The aging of our population is accompanied by an increased prevalence of chronic diseases. Among those, liver, joint and adipose tissue-related pathologies have a major socio-economic impact. They share common origins as they result from a dysregulation of the inflammatory and metabolic status. Plant-derived nutrients and especially polyphenols, exert a large range of beneficial effects in the prevention of chronic diseases but require clinically validated approaches for optimized care management. In this study, we designed an innovative clinical approach considering the metabolites produced by the digestive tract following the ingestion of an artichoke leaf extract. Human serum, enriched with metabolites deriving from the extract, was collected and incubated with human hepatocytes, human primary chondrocytes and adipocytes to determine the biological activity of the extract. Changes in cellular behavior demonstrated that the artichoke leaf extract protects hepatocytes from lipotoxic stress, prevents adipocytes differentiation and hyperplasia, and exerts chondroprotective properties in an inflammatory context. These data validate the beneficial health properties of an artichoke leaf extract at the clinical level and provide both insights and further evidence that plant-derived nutrients and especially polyphenols from artichoke may represent a relevant alternative for nutritional strategies addressing chronic disease issues.

31 August 2022 in Molecules
Verified
Journal Article
Open access
PDF file
AAAsma BOURAFAI AZIEZ
Asma BOURAFAI AZIEZ
DJDaniel Jacob
Daniel Jacob
GCgwladys charpentier
gwladys charpentier
ECEmmanuel Cassin
Emmanuel Cassin
GRGuillaume Rousselot
Guillaume Rousselot
Catherine DebordeCatherine Deborde
Catherine Deborde
Acerola (Malpighia emarginata D.C.) is an exotic fruit with high agro-industrial potential due to its high content of ascorbic acid (AA), phenolic compounds, and carotenoid pigments. Acerola fruit is processed into concentrated juice or powder to be incorporated into food supplements. The ascorbic acid content of concentrated juice or powders must be controlled and well assessed. Therefore, the development of optimal methods and procedures for the rapid and accurate determination of the ascorbic acid content in juice concentrate and juice powder remains of considerable commercial interest. NMR spectroscopy is currently a powerful spectroscopic tool for the qualitative and quantitative analysis of molecules of all types and sizes. Firstly, this article presents the NMR-based metabolomic profiling of acerola juice and concentrate powder to describe and compare their composition. Thirty-six metabolites were identified. The AA over choline ratio and the NMR metabolomic profiles could be used for authentication in the future. Secondly, a rapid (8 min), reliable, and non-destructive method for the quantification of ascorbic acid by 1D 1H-NMR spectroscopy was developed and validated. The LOD and LOQ were 0.05 and 0.15 mg/mL, respectively. These two approaches could be combined to better characterize ingredients derived from acerola and incorporated into food supplements.

29 October 2019 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
AAAsma BOURAFAI AZIEZ
Asma BOURAFAI AZIEZ
MSMuriel Sebban
Muriel Sebban
MBM. Benabderrahmane
M. Benabderrahmane
BMBogdan Marekha
Bogdan Marekha
CDC. Denis
C. Denis
HOHassan Oulyadi
Hassan Oulyadi
Myeloid cell leukemia-1 (Mcl-1) is an anti-apoptotic member of the Bcl-2 family proteins. Its amplification is one of the most frequent genetic aberrations found in human cancers. Pyridoclax, a promising BH3 mimetic inhibitor, interacts directly with Mcl-1 and induces massive apoptosis at a concentration of 15 µM in combination with anti-Bcl-xL strategies in chemo-resistant ovarian cancer cell lines. In this study, a combined experimental and theoretical approach was used to investigate the binding mode of Pyridoclax to Mcl-1. The representative poses generated from dynamics simulations compared with NMR data revealed: (i) Pyridoclax bound to P1 and P2 pockets of Mcl-1 BH3 binding groove through its styryl and methyl groups establishing mainly hydrophobic contacts, (ii) one of the ending pyridines interacts through electrostatic interaction with K234 side chain, a negatively charged residue present only in this position in Mcl-1. Communicated by Ramaswamy H. Sarma

1 December 2021 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
AAAsma BOURAFAI AZIEZ
Asma BOURAFAI AZIEZ
MBMohammed Benabderrahmane
Mohammed Benabderrahmane
HPHippolyte Paysant
Hippolyte Paysant
LWLouis-Bastien Weiswald
Louis-Bastien Weiswald
LPLaurent Poulain
Laurent Poulain
MSMuriel Sebban
Muriel Sebban
Introduction: With the aim of repositioning commercially available drugs for the inhibition of the anti-apoptotic myeloid cell leukemia protein, Mcl-1, implied in various cancers, five molecules, highlighted from a published theoretical screening, were selected to experimentally validate their affinity toward Mcl-1. Results: A detailed NMR study revealed that only two of the five tested drugs, Torsemide and Deferasirox, interacted with Mcl-1. NMR data analysis allowed the complete characterization of the binding mode of both drugs to Mcl-1, including the estimation of their affinity for Mcl-1. Biological assays evidenced that the biological activity of Torsemide was lower as compared to the Deferasirox, which was able to efficiently and selectively inhibit the anti-apoptotic activity of Mcl-1. Finally, docking and molecular dynamics led to a 3D model for the Deferasirox:Mcl-1 complex and revealed the positioning of the drug in the Mcl-1 P2/P3 pockets as well as almost all synthetic Mcl-1 inhibitors. Interestingly, contrary to known synthetic Mcl-1 inhibitors which interact through Arg263, Deferasirox, establishes a salt bridge with Lys234. Conclusion: Deferasirox could be a potential candidate for drug repositioning as Mcl-1 inhibitor.

13 February 2018 in Synthetic Communications
Verified
Journal Article
Closed access
AAASMA ARFAOUI
ASMA ARFAOUI
FSFatma Saâdi
Fatma Saâdi
AAAsma BOURAFAI AZIEZ
Asma BOURAFAI AZIEZ
HCHAMMOUDA CHEBBI
HAMMOUDA CHEBBI
CFCatherine Fressigné
Catherine Fressigné
HAHassen Amri
Hassen Amri
An efficient coupling reaction of allyl bromides with various alcohols as nucleophiles activated by triethylamine, leading to functionalized vinyl ethers in good yields and with full stereoselectivity.

3 April 2026
Verified
Thesis
Closed access
AAAsma BOURAFAI AZIEZ
Asma BOURAFAI AZIEZ
Le cancer de l’ovaire est la cinquième cause de décès par cancer chez la femme en France. La prolifération tumorale dans ce cancer est liée principalement à la dérégulation de l’apoptose. Cette dérégulation joue un rôle clé principalement dans la pathogénèse et la progression tumorale mais aussi dans le développement des résistances aux chimiothérapies existantes. La croissance accrue des cellules tumorales dans le cas du cancer de l’ovaire est liée à une surexpression des protéinesanti-apoptotiques de la famille Bcl-2, en particulier les protéines MCL-1 et Bcl-xL. L’inhibition concomitante de ces deux protéines conduit à la mort des cellules chimiorésistances. A ce jour, seuls les inhibiteurs de Bcl-xL ont démontré une efficacité en clinique, et l’inhibition de MCL-1 reste problématique dans un contexte clinique. Dans ce contexte, l’objectif principal de ces travaux de thèse consiste à caractériser, par RMN et modélisation moléculaire, l’interaction entre la protéine MCL-1 et le Pyridoclax, foldamère oligopyridinique très prometteur, synthétisé au CERMN. La spectroscopie RMN nous a permis de définir le site d’interaction, d’estimer la constante d’affinité et de guider le Docking pour obtenir une structure tridimensionnelle du complexe MCL-1:Pyridoclax. Afin de conforter notre étude sur l’implication du Pyridoclax dans l’interaction, des fragments dérivés de ce dernier ont été utilisés. La caractérisation de l’interaction entre ces fragments et la protéine MCL-1 a permis de relever l’importance du groupement styryle du Pyridoclax dans l’interaction avec la protéine MCL-1. Par ailleurs, nous avons élargi notre étude à d’autres inhibiteurs potentiels de MCL-1 tels que certains médicaments existant sur le marché. La spectroscopie RMN a permis de mettre en évidence et de caractériser l’interaction entre deux de ces médicaments (le Torsémide et le Déférasirox) et la protéine MCL-1. Pour finir, afin d’améliorer l’affinité de ces médicaments pour la protéine MCL-1, des modifications structurales ont été proposés en se basant sur la littérature. Les dérivés proposés semblent avoir une affinité très importante pour la protéine MCL-1.